Literature DB >> 23276965

Human neuromelanin: an endogenous microglial activator for dopaminergic neuron death.

Wei Zhang1, Luigi Zecca, Belinda Wilson, Hong-Wei Ren, Yong-Jun Wang, Xiao-Min Wang, Jau-Shyong Hong.   

Abstract

Substantial evidence indicates that neuroinflammation caused by microglial activation in substantia nigra is critical in the pathogenesis of dopaminergic neurodegeneration in Parkinson's disease (PD). Increasing data demonstrates that environmental factors such as rotenone, paraquat play pivotal roles in dopaminergic neuron death. Here, potential role and mechanism of neuromelanin (NM), a major endogenous component in dopaminergic neurons of substantia nigra, on microglial activation and associated dopaminergic neurotoxicity were investigated. Using multiple primary mesencephalic cultures, we found that HNM caused dopaminergic neurodegeneration characterized by the decreased dopamine uptake and reduced numbers and shorted dendrites. HNM was selectively toxic to dopaminergic neurons since the other types of neurons determined by either gamma-aminobutyric acid uptake and total neuronal numbers showed smaller decrease. HNM produced modest dopaminergic neurotoxicity in neuron-enriched cultures; in contrast, much greater neurotoxicity was observed in the presence of microglia. HNM morphologically activated microglia and produced proinflammatory and neurotoxic factors. Thus, HNM can be a potent endogenous activator of microglial reactivation, mediating PD progression. Hence, inhibition of microglial reactivation can be a useful strategy for PD therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23276965      PMCID: PMC3626451          DOI: 10.2741/e591

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  27 in total

1.  Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration.

Authors:  Liya Qin; Xuefei Wu; Michelle L Block; Yuxin Liu; George R Breese; Jau-Shyong Hong; Darin J Knapp; Fulton T Crews
Journal:  Glia       Date:  2007-04-01       Impact factor: 7.452

2.  3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity.

Authors:  Wei Zhang; Liya Qin; Tongguang Wang; Sung-Jen Wei; Hui-ming Gao; Jie Liu; Belinda Wilson; Bin Liu; Wanqin Zhang; Hyoung-Chun Kim; Jau-Shyong Hong
Journal:  FASEB J       Date:  2004-12-13       Impact factor: 5.191

Review 3.  Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism.

Authors:  Michelle L Block; Jau-Shyong Hong
Journal:  Prog Neurobiol       Date:  2005-06       Impact factor: 11.685

4.  Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells.

Authors:  M Shamoto-Nagai; W Maruyama; Y Akao; T Osawa; F Tribl; M Gerlach; F A Zucca; L Zecca; P Riederer; M Naoi
Journal:  J Neural Transm (Vienna)       Date:  2004-10       Impact factor: 3.575

5.  Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease.

Authors:  Wei Zhang; Kester Phillips; Albert R Wielgus; Jie Liu; Alberto Albertini; Fabio A Zucca; Rudolph Faust; Steven Y Qian; David S Miller; Colin F Chignell; Belinda Wilson; Vernice Jackson-Lewis; Serge Przedborski; Danielle Joset; John Loike; Jau-Shyong Hong; David Sulzer; Luigi Zecca
Journal:  Neurotox Res       Date:  2009-12-03       Impact factor: 3.911

6.  Parkinsonism and extraocular motor abnormalities with unusual neuropathological findings.

Authors:  V P Calabrese; M G Hadfield
Journal:  Mov Disord       Date:  1991       Impact factor: 10.338

Review 7.  The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery.

Authors:  Garima Dutta; Ping Zhang; Bin Liu
Journal:  Fundam Clin Pharmacol       Date:  2008-08-15       Impact factor: 2.748

Review 8.  Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.

Authors:  Malú G Tansey; Matthew S Goldberg
Journal:  Neurobiol Dis       Date:  2009-11-10       Impact factor: 5.996

9.  Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease.

Authors:  Vanesa Sanchez-Guajardo; Fabia Febbraro; Deniz Kirik; Marina Romero-Ramos
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

10.  Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles.

Authors:  D Sulzer; J Bogulavsky; K E Larsen; G Behr; E Karatekin; M H Kleinman; N Turro; D Krantz; R H Edwards; L A Greene; L Zecca
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

View more
  18 in total

Review 1.  Neuromelanin of the human substantia nigra: an update.

Authors:  Fabio A Zucca; Emy Basso; Francesca A Cupaioli; Emanuele Ferrari; David Sulzer; Luigi Casella; Luigi Zecca
Journal:  Neurotox Res       Date:  2013-10-24       Impact factor: 3.911

2.  Inflaming the diseased brain: a role for tainted melanins.

Authors:  T M Jeitner; M Kalogiannis; P A Patrick; I Gomolin; T Palaia; L Ragolia; D Brand; E J Delikatny
Journal:  Biochim Biophys Acta       Date:  2015-01-10

Review 3.  Melanin affinity and its possible role in neurodegeneration.

Authors:  Oskar Karlsson; Nils Gunnar Lindquist
Journal:  J Neural Transm (Vienna)       Date:  2013-07-03       Impact factor: 3.575

4.  Translocator Protein Ligand Protects against Neurodegeneration in the MPTP Mouse Model of Parkinsonism.

Authors:  Jing Gong; Éva M Szego; Andrei Leonov; Eva Benito; Stefan Becker; Andre Fischer; Markus Zweckstetter; Tiago Outeiro; Anja Schneider
Journal:  J Neurosci       Date:  2019-02-22       Impact factor: 6.167

5.  Synthesis and biological evaluation of substituted N-[3-(1H-pyrrol-1-yl)methyl]-1,2,5,6-tetrahydropyridin-1-yl]benzamide/benzene sulfonamides as anti-inflammatory agents.

Authors:  Madhavi Gangapuram; Elizabeth Mazzio; Suresh Eyunni; Karam F A Soliman; Kinfe K Redda
Journal:  Arch Pharm (Weinheim)       Date:  2014-03-02       Impact factor: 3.751

Review 6.  Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease.

Authors:  Georgia S Gaki; Athanasios G Papavassiliou
Journal:  Neuromolecular Med       Date:  2014-02-13       Impact factor: 3.843

Review 7.  Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease.

Authors:  Fabio A Zucca; Juan Segura-Aguilar; Emanuele Ferrari; Patricia Muñoz; Irmgard Paris; David Sulzer; Tadeusz Sarna; Luigi Casella; Luigi Zecca
Journal:  Prog Neurobiol       Date:  2015-10-09       Impact factor: 11.685

Review 8.  Toxic Feedback Loop Involving Iron, Reactive Oxygen Species, α-Synuclein and Neuromelanin in Parkinson's Disease and Intervention with Turmeric.

Authors:  Zuné Jansen van Rensburg; Shameemah Abrahams; Soraya Bardien; Colin Kenyon
Journal:  Mol Neurobiol       Date:  2021-08-23       Impact factor: 5.590

9.  MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration.

Authors:  Carolina Cebrián; Fabio A Zucca; Pierluigi Mauri; Julius A Steinbeck; Lorenz Studer; Clemens R Scherzer; Ellen Kanter; Sadna Budhu; Jonathan Mandelbaum; Jean P Vonsattel; Luigi Zecca; John D Loike; David Sulzer
Journal:  Nat Commun       Date:  2014-04-16       Impact factor: 14.919

Review 10.  Neuronal MHC-I expression and its implications in synaptic function, axonal regeneration and Parkinson's and other brain diseases.

Authors:  Carolina Cebrián; John D Loike; David Sulzer
Journal:  Front Neuroanat       Date:  2014-10-13       Impact factor: 3.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.